

INTRABIOTICS PHARMACEUTICALS INC /DE
Form SC 13D/A
May 01, 2003

OMB APPROVAL

OMB Number 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response 11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.)*

INTRABIOTICS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

46116T 10 0

(CUSIP Number)

Kevin C. Tang
Tang Capital Management, LLC
4401 Eastgate Mall
San Diego, CA 92121
(858) 200-3831

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 1, 2003

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [X].

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Tang Capital Partners, LP

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

NUMBER OF 7. Sole Voting Power
SHARES 1,417,741*

BENEFICIALLY 8. Shared Voting Power
OWNED BY 0
EACH

REPORTING 9. Sole Dispositive Power
PERSON 1,417,741*
WITH

10. Shared Dispositive Power
0

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,417,741*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
31.2%

14. Type of Reporting Person (See Instructions)
PN

* Represents 139,279 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Tang Capital Management, LLC

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

	7. Sole Voting Power
NUMBER OF	1,417,741*
SHARES	-----
BENEFICIALLY	8. Shared Voting Power
OWNED BY	0
EACH	-----
REPORTING	9. Sole Dispositive Power
PERSON	1,417,741*
WITH	-----
	10. Shared Dispositive Power
	0

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,417,741*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
31.2%

14. Type of Reporting Person (See Instructions)
OO

* Represents 139,279 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

CUSIP No. 46116T 10 0

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Kevin C. Tang

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
WC

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

- | | |
|--|------------------------------|
| NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH | 7. Sole Voting Power |
| | 1,417,741* |
| | 8. Shared Voting Power |
| | 0 |
| | 9. Sole Dispositive Power |
| | 1,417,741* |
| | 10. Shared Dispositive Power |
| | 0 |

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,417,741*

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
31.2%

14. Type of Reporting Person (See Instructions)
IN

* Represents 139,279 shares of common stock, shares of preferred stock convertible into 852,308 shares of common stock, and warrants to purchase up to 426,154 shares of common stock.

CUSIP No. 46116T 10 0

1. Name of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Oscar L. Tang

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

2. Check the Appropriate Box If a Member of a Group (See Instructions)
(a)
(b) Joint-Filing

3. SEC Use Only

4. Source of Funds (See Instructions)
PF

5. Check If Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)

6. Citizenship or Place of Organization
United States

7. Sole Voting Power
NUMBER OF 23,408
SHARES

8. Shared Voting Power
BENEFICIALLY OWNED BY EACH 9,539
PERSON WITH

9. Sole Dispositive Power
23,408

10. Shared Dispositive Power
9,539

11. Aggregate Amount Beneficially Owned by Each Reporting Person
32,947

12. Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)

13. Percent of Class Represented by Amount in Row (11)
1.0%

14. Type of Reporting Person (See Instructions)
IN

ITEM 1. SECURITY AND ISSUER

This statement relates to Intrabiotics Pharmaceuticals, Inc. Common Stock. The principal executive offices of the issuer are located at 2483 East Bayshore Road, Suite 100, Palo Alto, CA 94303.

ITEM 2. IDENTITY AND BACKGROUND

The name, business address and present principal occupation or business of each of the persons filing this statement are as follows:

Tang Capital Partners, LP is a capital management company. The business address of Tang Capital Partners, LP is c/o Tang Capital Management, LLC at such address shown below.

Tang Capital Management, LLC is the general partner of Tang Capital Partners, LP. The business address of Tang Capital Management, LLC is

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

4401 Eastgate Mall, San Diego, CA 92121.

Kevin C. Tang is the Manager of Tang Capital Management, LLC. The business address of Kevin C. Tang is c/o Tang Capital Management, LLC at such address shown above.

Oscar L. Tang is a private investor. The business address of Oscar L. Tang is c/o Reich & Tang Asset Management LLC, 600 Fifth Avenue, 8th Floor, New York, NY 10020.

None of the persons filing this statement has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

None of the persons filing this statement has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Each of the persons filing this statement is a citizen of the United States of America.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

On May 1, 2003, Tang Capital Partners, LP purchased 162 shares of Series A Preferred Stock and warrants to purchase up to 426,154 shares of Common Stock of the issuer. The shares of Series A Preferred Stock are convertible into 852,308 shares of Common Stock of the issuer. The Warrants will have a term of five years and are exercisable at an exercise price of \$2.066 per share.

Prior to acquiring such securities, Tang Capital Partners, LP, Tang Capital Management, LLC and Kevin C. Tang beneficially owned 139,279 shares of Common Stock and Oscar L. Tang beneficially owned 32,947 shares of Common Stock. The prior beneficial ownership was previously reported by the reporting persons on Schedule 13G filed on March 4, 2003.

The funds used to purchase the securities referenced above were from working capital of Tang Capital Partners, LP, with respect to the securities beneficially owned by Tang Capital Partners, LP, Tang Capital Management, LLC and Kevin C. Tang, and from personal funds with respect to the securities beneficially owned by Oscar L. Tang.

No funds used to acquire the issuer's securities by the reporting persons were borrowed or otherwise obtained.

ITEM 4. PURPOSE OF TRANSACTION

The May 1, 2003 transaction described in Item 3 occurred as a result of negotiations between Tang Capital Partners, LP and the issuer. Tang Capital Partners, LP is acquiring the securities for investment purposes and to acquire a strategic interest and influence the control of the issuer. Depending on market conditions, the reporting persons may increase or decrease their beneficial ownership of the shares of Common Stock of the issuer.

Tang Capital Partners, LP has the right to designate two board members as representatives of the Series A Preferred Stock holders. In connection with the purchase, Kevin C. Tang will be designated as a member of the issuer's board of directors to serve as a representative of the holders of Series A Preferred Stock. In his capacity as a director of the issuer, Kevin C. Tang will participate in decisions made by the board of directors in the ordinary course

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

of business of the issuer. Except as may arise in connection with the normal execution of his position as a director, or as provided in this paragraph, none of the persons filing this statement has any present plans or proposals which relate to or would result in (a) the acquisition by any person of additional securities of the issuer (other than the acquisition of Common Stock upon conversion of Series A Preferred Stock or exercise of Warrants as described herein), or the disposition of securities of the issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the issuer (other than the designation of an additional Series A Preferred Stock holder representative to the board as described herein), including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the issuer; (f) any other material change in the issuer's business or corporate structure; (g) changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.

Any of the reporting persons may from time to time acquire or dispose of issuer securities. Such acquisitions or dispositions may be made in the open market or in privately negotiated transactions.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) The aggregate number and percentage of securities to which this Schedule 13D relates is 1,450,688 shares, representing approximately 31.9% of the 3,269,168 shares of Common Stock outstanding as reported by the issuer in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2003 (and taking into account in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, a total of 852,308 shares of Common Stock issuable upon conversion of Series A Preferred Stock held as described herein and 426,154 shares of Common Stock issuable upon exercise of the Warrants held as described herein.) The reporting persons beneficially own the securities set forth below:

Name	Shares	% of Class
-----	-----	-----
Tang Capital Partners, LP	1,417,741	31.2%
Tang Capital Management, LLC	1,417,741	31.2%
Kevin C. Tang	1,417,741	31.2%
Oscar L. Tang	32,947	1.0%

(b) Number of shares to which such person has:

(i) Sole power to vote or direct the vote:

Tang Capital Partners, LP	1,417,741 shares
Tang Capital Management, LLC	1,417,741 shares
Kevin C. Tang	1,417,741 shares
Oscar L. Tang	23,408 shares

(ii) Shared power to vote or direct the vote:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

Kevin C. Tang	0 shares
Oscar L. Tang	9,539 shares

(iii) Sole power to dispose or direct the disposition of:

Tang Capital Partners, LP	1,417,741 shares
Tang Capital Management, LLC	1,417,741 shares
Kevin C. Tang	1,417,741 shares
Oscar L. Tang	23,408 shares

(iv) Shared power to dispose or direct the disposition of:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares
Kevin C. Tang	0 shares
Oscar L. Tang	9,539 shares

Oscar L. Tang's shares' voting and dispositive powers are through an investment advisor or trustee relationship for various family members.

(c) Other than the May 1, 2003 purchase described in Item 4, none of the reporting persons has effected any transactions in the issuer's Common Stock within the past sixty days.

(d) Not applicable.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

Tang Capital Partners, LP is the registered holder of the issuer Common Stock, Series A Preferred Stock and Warrants. Tang Capital Management, LLC is the general partner of Tang Capital Partners, LP. Kevin C. Tang is the Manager of Tang Capital Management, LLC.

Each of Kevin C. Tang and Oscar L. Tang owns a limited partnership interest in Tang Capital Partners, LP and disclaims any beneficial ownership in the issuer securities reported by Tang Capital Partners, LP other than his pecuniary interest therein. Kevin C. Tang is the son of Oscar L. Tang.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit A	Agreement of Joint Filing, dated May 1, 2003
Exhibit B	Certificate of Amendment of Amended and Restated Certificate of Incorporation of Intrabiotics Pharmaceuticals, Inc. (incorporated by reference from Appendix A of the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 3, 2003)
Exhibit C	Preferred Stock and Warrant Purchase Agreement (incorporated by reference from Appendix B of the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 3, 2003)
Exhibit D	Intrabiotics Pharmaceuticals, Inc. Certificate of Designation of Series A Convertible Preferred Stock (incorporated by reference from Appendix C of the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 3, 2003)
Exhibit E	Warrant to Purchase Shares of Common Stock of Intrabiotics Pharmaceuticals, Inc. (incorporated by reference from Appendix D of the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 3, 2003)
Exhibit F	Stockholder Agreement (incorporated by reference from Appendix E

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

of the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 3, 2003)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TANG CAPITAL PARTNERS, LP
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

/s/ Kevin C. Tang

KEVIN C. TANG

/s/ Oscar L. Tang

OSCAR L. TANG

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)

EXHIBIT A
TO SCHEDULE 13D
DATED MAY 1, 2003

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13D/A

amendments thereto) with respect to the Common Stock of Intrabiotics Pharmaceuticals, Inc. and that this Agreement be included as an Exhibit to such joint filing. The Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 1st day of May, 2003.

TANG CAPITAL PARTNERS, LP
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang

Kevin C. Tang, Manager

/s/ Kevin C. Tang

KEVIN C. TANG

/s/ Oscar L. Tang

OSCAR L. TANG